THE LOVESAC COMPANY (LOVE): what the price assumes
In the published model solve dated 2026-Q2, anchored at $16.69, THE LOVESAC COMPANY (LOVE) is priced for today's economics sustained for ~5.2 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-29.
Generated: 2026-07-29 · Source: https://boothcheck.com/report/LOVE
Headline
| Field | Value |
|---|---|
| Ticker | LOVE |
| Company | THE LOVESAC COMPANY |
| Sector / Industry | Consumer Cyclical |
| Current price | $16.69/sh |
What The Price Assumes (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin (value-band context) | 0.3% |
| Operating margin (mid-cycle) | 2.0% |
| Margin compression (value-band) | -1.7pp |
| Trailing margin (depressed year) | 0.4% |
| Must persist for | 5.2y |
| Multiple paid | 37x mid-cycle operating income |
The operating-margin figure is value-band context at year 10: derived from the framework's value band, a separate calculation — not part of the priced-in solve.
Solve inputs: computed at a 8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2 years.
Reconcile: at the x-ray's 9.3% required return this reads ~7.7 years; the models below use their own rates.
How unusual the bet is: elevated
| Reference | Value |
|---|---|
| vs own history | +0.58σ |
| sustained it ~5.2 years at this level | 29% |
| implied end-window share | 0% |
Valuation X-Ray
Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 8.32x | 4 | expensive |
| Earnings | 4.52x | 2 | expensive |
| Relative | 1.53x | 2 | expensive |
| Growth | 0.79x | 3 | justifies |
Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.1%); the inversion above states its own rate.
Per-Model Detail (n=11)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $30.12 | 0.55x | yes | FCF base $0.0B, growth 1% (input: historical growth), terminal g 1.3%, WACC 6.1%, 7yr projection |
| DCF Exit Multiple | Growth | $21.11 | 0.79x | yes | Exit EV/EBITDA: 24.2x / 29.2x / 34.2x (bear / base = today's held flat / bull), 7yr |
| Relative Valuation | Relative | $5.90 | 2.83x | yes | P/E 33.27x (blended: static sector reference 20x + trailing (TTM) 64x), scenarios: 23.3x / 33.3x / 43.3x (bear / base = reference held flat / bull), EV/EBITDA 18.55x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $2.81 | 5.94x | yes | BV/sh $14.01, ROE (TTM) 1.9%, ke 9.3% |
| Two-Stage Excess Return | Asset | $1.56 | 10.70x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $11.26 | 1.48x | yes | Rev $0.7B, growth 1% (input: historical growth; tapered), Terminal P/S: 0.2x / 0.4x / 0.5x (bear / base = today's held flat / bull, cap 15x) |
| Growth-Adjusted P/E | Relative | — | — | no | — |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $0.01 | 1669.00x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.02B × (1−21%) / WACC 6.1% → EPV (no growth) (excluded from median) |
| Residual Income | Asset | $1.13 | 14.77x | yes | BV $14.01 + 5yr PV of (ROE (TTM) 1.9% − Kₑ 9.3%) × BV; BV grows 1.2%/yr |
| Graham Number | Asset | $8.88 | 1.88x | yes | √(22.5 × EPS $0.25 × BVPS $14.01) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $0.01 | 1669.00x | yes | EBITDA $0.02B × sector EV/EBITDA 14.0x (excluded from median) |
| FCF Yield | Earnings | $5.84 | 2.86x | yes | FCF $35.8M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $0.01 | 1669.00x | yes | SBC-adj FCF $0.03B (FCF $0.04B − SBC $0.01B) capitalized at Kₑ (excluded from median) |
| Ben Graham Formula | Earnings | $0.21 | 79.48x | yes | EPS $0.25 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median) |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $71.27 | 0.23x | yes | Revenue $0.70B × sector P/S 1.5x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | $2.70 | 6.18x | yes | EPS $0.25 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net cash | $57.0m |
| Net debt / NOPAT (after-tax) | -5.16x (net cash) |
| Net debt / operating income (pre-tax) | -4.08x (net cash) |
| Share count CAGR (buyback) | -2.4% |
| Burning cash | no |
Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 2.0%); the trailing year was depressed.
Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.
Bullet Takeaways
- Lovesac sells one idea in several forms: modular seating the company says is built to last a lifetime and designed to evolve as our customers' lives do, with all of our core products protected by a robust portfolio of utility and design patents.
- Showrooms are taking share from every other channel, at 67.1%, 62.6% and 62.5% of total net sales for fiscal 2026, 2025 and 2024, which is the opposite of the direction most furniture retail has travelled.
- The trailing operating margin is 0.4 percent against a through-cycle figure nearer 2 percent, so the price is being set on a normalized earnings power the company is not currently demonstrating.
Bull Case
The moat here is a patent portfolio wrapped around a purchase decision that repeats. Lovesac's core products are modular couches called Sactionals®, premium foam beanbag chairs called Sacs®, the immersive surround sound home theater system called StealthTech®, the PillowSac® Chair, the Sactionals Reclining Seat, a recently launched platform called Snugg, and the filing is explicit that all of our core products protected by a robust portfolio of utility and design patents. Modularity is what turns that legal position into an economic one. A customer who buys a Sactional has bought a system, and every later seat, cover or accessory has to fit the system they already own.
The company frames this as its Designed For Life approach, products built to last a lifetime and designed to evolve with our customers' lives, and notes that customers generally invest in them with that expectation. Read as an economic claim rather than a marketing one, that is a business whose second sale costs almost nothing to acquire. The filing says as much from the other direction, describing growth that depends on referrals from existing customers and warning what happens if satisfaction slips.
The channel data supports the story rather than merely accompanying it. Showroom net sales ran 67.1%, 62.6% and 62.5% of total net sales for fiscal 2026, 2025 and 2024, respectively. Physical retail gaining six points of mix in two years is unusual in any consumer category and particularly so in furniture, where the industry narrative has been the reverse for a decade. It is consistent with a product that has to be sat on to be understood.
Capital allocation matches. The share count shrank about 2.4 percent a year over the four years to May 2026, and the company carries no funded borrowings at all. A retailer expanding its store base while retiring stock and running without leverage is funding growth from the business. The trailing margin is thin, but through the cycle this company has earned nearer 2 percent, and normalized on that basis operating profit is roughly 14 million dollars rather than the 2.9 million the trough year shows.
Bear Case
Nothing in a patent portfolio stops a larger competitor from outspending you for the customer. The filing names the mechanism precisely: competitors may acquire customers at lower costs and respond more quickly than we can to new or emerging technologies and changes in consumer habits. These competitors may engage in more extensive research and development efforts, undertake more far-reaching marketing campaigns and adopt more aggressive pricing policies. Design patents protect a form. They do not protect a price point, and modular seating has been on the market long enough that the category no longer surprises anyone.
That matters more than usual because this business runs on referral. The company acknowledges that if our efforts to satisfy our existing customers are not successful, we may not be able to acquire new customers or reactivate prior customers through these referrals, which may adversely affect how we continue to grow our business, or may require us to incur significantly higher marketing expenses. A referral engine is cheap while it works and expensive the moment it stops, and the cost shows up as marketing spend against a margin that has very little room in it.
The margin is the second problem. The trailing year produced 2.9 million dollars of operating profit on roughly 736 million of revenue, a 0.4 percent operating margin. The company's own through-cycle figure is nearer 2 percent, and the valuation rests on getting back there. Between those two numbers sits a discretionary big-ticket purchase in a category consumers defer indefinitely when they are uncertain. Trailing net income came in slightly above operating profit, which means items below the operating line are flattering the bottom of the statement rather than the business doing better than it appears.
Then the growth requirement itself. Expanding the showroom base is the plan, and the filing concedes the risk in that plan: the company may not sustain the sales growth rates that we have achieved historically as we continue to expand our showroom base, and expansion may result in the closure of underperforming showroom locations or locations with declining profitability. Store-based growth is not linear. The first hundred locations take the best sites; what follows is progressively harder, and the price assumes a long run of it.
Valuation
The unusual thing about this price is not how much growth it needs but how long it needs it for. Today's price works out to roughly 37 times company-wide normalized operating profit, and inverting that under a 25 percent self-funding growth ceiling implies the company holds growth at that ceiling for about 5.2 years. The near-term pace is within what Lovesac has recently delivered. The stretch is entirely in the persistence, and at a sensitivity of roughly 2 years per percentage point, small changes in the achievable rate move the required horizon a lot.
Note which earnings base that multiple sits on, because it is not the trailing one. Trailing operating profit for the year ending in early May 2026 was 2.9 million dollars, a 0.4 percent margin. The valuation instead uses the company's own through-the-cycle margin of about 2 percent applied to current revenue, giving normalized operating profit near 14 million. Both figures are real and they describe different things: one is what this year earned, the other is what this revenue base has historically earned. The multiple only makes sense against the second, and the reader should know that is the swap being made.
The families split cleanly, which tells you what kind of bet this is. Only the forward-growth family reaches the price, landing slightly above it. The peer-multiple family sits at a premium of about half again, earnings power at roughly four and a half times, and asset value at more than eight times. When the static frames are that far below and only the growth frame arrives, the premium is a durability claim: the price is paying for compounding that backward-looking methods structurally cannot encode. That is a legitimate thing to pay for and an easy thing to be wrong about.
The balance sheet removes one worry and cannot remove the other. There are no funded borrowings, the share count has been shrinking rather than growing, and the company is not burning cash. Interest coverage cannot be computed because interest expense is not separately reported in the latest filings, which is itself a signal about how little debt matters here. What that leaves is a pure operating question. Five years is a long time to hold a ceiling growth rate, and nothing on the balance sheet makes it shorter.
Catalysts
Showroom mix is the most informative single line in the next print. It has moved 67.1%, 62.6% and 62.5% of total net sales for fiscal 2026, 2025 and 2024, respectively, and a fourth consecutive year of showrooms gaining share would say the format is doing the work rather than benefiting from a soft comparison in ecommerce. A reversal would say the opposite about a plan built on opening more of them.
Margin recovery is the second thing to watch and the one the valuation actually depends on. The gap between a 0.4 percent trailing operating margin and a through-cycle figure nearer 2 percent is the entire normalization the price assumes. Watch whether operating profit moves toward the through-cycle level on the current revenue base rather than waiting on revenue growth to carry it there, because the price already assumes both.
Store-opening cadence carries information in either direction. The filing warns that continued expansion may result in the closure of underperforming showroom locations or locations with declining profitability in order to pursue more productive opportunities. Net openings tell you the plan is on track; a stretch of closures alongside openings tells you the site quality curve has started to bite, which is the specific way store-based growth stories usually end.
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.